HAC Pharma

What HAC Pharma does

H.A.C. Pharma is an independent French pharmaceutical laboratory headquartered in Caen, France, founded in 2007 by Philippe Bissay and Pascal Sery. The company acquires, registers, and markets established specialty medications across 8 therapeutic areas—cardiology, endocrinology, gastroenterology, nutrition, onco-hematology, pneumology, and rheumatology—via a portfolio of 15 products including Aldomet, Trandate, Imurel, Esbriet, Targretin, and Trophicreme. Its stated purpose is to maintain continuity of supply for essential and proven drugs that larger originators have discontinued or deprioritized.

The business model is fundamentally a specialty-pharma "acquire-and-maintain" platform: H.A.C. Pharma sources products through licensing and asset acquisitions from major multinationals (notably Roche's Esbriet European/UK rights in November 2025, Eisai's Targretin in January 2025, Sanofi's Trophicreme in October 2024, and earlier Aldomet/Indocid in 2017) and monetizes them through regulated prescription sales to hospitals, pharmacies, and clinicians in 7 European countries. Revenue is reported at €33 million with approximately 35 employees, with pricing set by French (HAS/CEPS) and European health authority frameworks rather than market pricing.

Go-to-market is exclusively B2B via country-specific distribution and pharmacovigilance partners: Alloga (France/Italy), Sanova (Austria), Lanners and Cophana (Belgium), Angelini (Portugal), Euromed Pharma and Galeapharma (Spain), and Virel (Italy). Commercial motion combines medical-rep promotion, medical congresses, and continuing-medical-education webinars targeting prescribing specialists. The company is incorporated as a Société par Actions Simplifiée (SAS) with capital of €1,000,000 and operates without a parent company, public listing, or institutional investment backing.

Name

HAC Pharma

Legal name

H.A.C. Pharma

Website

https://hacpharma.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

H.A.C. Pharma is an independent French pharmaceutical laboratory that acquires and markets 15 established specialty medications across 8 therapeutic areas, selling to hospitals, physicians, and pharmacies in 7 European countries.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Specialty pharmaceuticals
• Hospital medicines
• Pharmaceutical distribution
• Pharmacovigilance services
• Therapeutic products

Headquarters

HQ city

Caen

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical product sales: Revenue generated from the sale of specialty pharmaceutical products. The company acquires and maintains rights to essential medications, ensuring their availability in the French and European markets. The company has made significant acquisitions including ESBRIET from Roche (November 2025), TARGRETIN from Eisai (January 2025), and TROPHICREME from Sanofi (October 2024).

Pricing tiers

Go-to-market motion1 record

Distribution channels6 records

Marketing channels3 records

Core offering

H.A.C. Pharma is an independent French pharmaceutical laboratory that acquires, holds, and distributes a portfolio of 15 specialty pharmaceutical products across 8 therapeutic areas (cardiology, endocrinology, gastroenterology, nutrition, onco-hematology, pneumology, rheumatology). The company manufactures at its Caen plant, holds marketing authorisations (AMM) for its portfolio, and provides pharmacovigilance and medical information services to healthcare professionals across 7 European countries.

Product overview

H.A.C. Pharma is an independent French pharmaceutical laboratory founded in 2007 that operates a portfolio of 15 pharmaceutical specialties across 8 therapeutic areas (Cardiology, Endocrinology, Gastroenterology, Nutrition, Onco-hematology, Pneumology, Rheumatology). The company specializes in maintaining the availability of essential and proven medications on the market, managing supply to the French market, ensuring healthcare professionals and patients are properly informed, and monitoring pharmacovigilance. The product portfolio includes cardiovascular drugs (Aldomet®, Trandate®), endocrine treatments (Flucortac®, Propylex®), immunosuppressants (Imurel®), oncology medications (Alkeran®, Lanvis®, Myleran®, Purinethol®), nutrition products (Dialypro®), anti-inflammatory treatments (Chrono-Indocid®, Indocid®), uric acid reducers (Zyloric®), and respiratory treatments (Esbriet®).

Differentiator

Problem solved

Functional benefit

Products and services

• Aldomet® Antihypertensive medication containing Methyldopa (INN), available as 250mg and 500mg coated tablets for the treatment of hypertension. Distributed in Austria, Belgium, France, Italy, Portugal, Spain, and Switzerland.
• Trandate® Beta-blocker medication containing Labetalol (ATC code C07AG01), available as 200mg tablets and 5mg/mL solution for injection for cardiovascular applications.
• Flucortac® Mineralocorticoid medication containing Fludrocortisone (ATC code H02AA02), available as 50µg scored tablets and 100µg/mL oral solution for endocrine replacement therapy.
• Propylex® Antithyroid medication containing Propylthiouracil (ATC code H03BA02), available as 50mg tablets for treatment of thyroid disorders.
• Imurel® Immunosuppressant medication containing Azathioprine (ATC code L04AX01), available as 25mg and 50mg film-coated tablets and 50mg powder for solution for injection for gastroenterology and transplant applications.
• Dialypro® Oral dietary supplement in powder form for nutritional support.
• Alkeran® Chemotherapy medication containing Melphalan (ATC code L01AA03), available as 2mg film-coated tablets for cancer treatment.
• Lanvis® Antimetabolite medication containing Thioguanine (ATC code L01BB03), available as 40mg tablets for onco-hematology treatment.
• Myleran® Chemotherapy medication containing Busulfan (ATC code L01AB01), available as 2mg film-coated tablets for onco-hematology treatment.
• Purinethol® Purine analog chemotherapy medication containing Mercaptopurine (ATC code L01BB02) for cancer treatment.
• Esbriet® Anti-fibrotic medication containing Pirfenidone, available as 267mg and 801mg film-coated tablets for treatment of idiopathic pulmonary fibrosis.
• Chrono-Indocid® Non-steroidal anti-inflammatory medication containing Indometacin (ATC code M01AB01), available as 75mg capsules for rheumatology applications. Distributed in Austria, France, Portugal, Spain, and Switzerland.
• Indocid® Non-steroidal anti-inflammatory medication containing Indometacin, available as 25mg capsules and 100mg suppositories for rheumatology applications. Distributed in Austria, France, Portugal, and Spain.
• Zyloric® Hypo-uricemic medication containing Allopurinol (ATC code M04AA01), available as 100mg and 300mg tablets for treatment of gout and hyperuricemia.
• Targretin® Hematology specialty medication containing Bexarotene for onco-hematology treatment, with European and UK rights acquired from Eisai.
• Trophicreme® Gynecology specialty medication containing Estriol acquired from Sanofi for women's health applications.

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

13 partnerships are on record, tiered core and minor.

• AllogacoreChannel Partner/ Reseller/ DistributorAlloga is a pharmaceutical logistics and distribution partner handling hospital product orders and distribution for H.A.C. Pharma in France and Italy.
• AngelinicoreChannel Partner/ Reseller/ DistributorAngelini serves as the local distribution partner for H.A.C. Pharma products in Portugal.
• ARAC AT REGULATORY AFFAIRS CONSULTING GMBHcoreImplementation/ SI/ Consulting PartnerARAC provides regulatory affairs consulting and pharmacovigilance services for H.A.C. Pharma in Austria.
• Aspen FranceminorChannel Partner/ Reseller/ DistributorDistribution agreement relationship established in 2008-2009 for Aspen products in the French market.
• BCN FarmaminorChannel Partner/ Reseller/ DistributorPharmaceutical distribution partner listed on the partnerships page.
• CophanaminorChannel Partner/ Reseller/ DistributorPharmaceutical distribution partner in Belgium for product availability and sales desk services.
• COPHANAminorChannel Partner/ Reseller/ DistributorBelgian pharmaceutical partner handling product distribution and customer service.
• EUROMED PHARMAcoreChannel Partner/ Reseller/ DistributorSpanish partner handling medical information, quality claims, and product availability for H.A.C. Pharma products in Spain.
• GALEAPHARMAcoreChannel Partner/ Reseller/ DistributorSpanish partner handling pharmacovigilance and product distribution in Spain.
• LANNERS ConsultingcoreChannel Partner/ Reseller/ DistributorPhilippe LANNERS represents H.A.C. Pharma in Belgium for medical information and product availability.
• NextpharmaminorChannel Partner/ Reseller/ DistributorPharmaceutical logistics and distribution partner listed on the partnerships page.
• SANOVA PharmacoreChannel Partner/ Reseller/ DistributorAustrian pharmaceutical partner handling product availability and customer care for H.A.C. Pharma products.
• VIREL PHARMAcoreChannel Partner/ Reseller/ DistributorItalian partner handling pharmacovigilance for H.A.C. Pharma products in Italy.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Almirall: Spanish specialty pharmaceutical company focused on dermatology and specialty therapeutics through licensing and acquisitions. Highly comparable independent European specialty pharma with a buy-and-develop model similar to HAC Pharma.
• Recordati: Italian specialty pharma group with strong European footprint in rare diseases, cardiology, and onco-hematology. Comparable in therapeutic-area coverage and specialty-drug acquisition strategy; larger but operating in adjacent European markets.
• Stada Arzneimittel: German-based European generics and specialty pharma company that acquires mature brands from big pharma. Highly comparable business model of acquiring off-patent and specialty assets across European geographies.
• Faes Farma: Spanish specialty pharma focused on licensing, manufacturing, and marketing mature specialty drugs. Comparable in therapeutic breadth, EU footprint, and acquisition-led growth.
• Sobi (Swedish Orphan Biovitrum): Swedish specialty pharma focused on rare diseases and specialty therapeutics, often acquiring late-stage or deprioritized assets from larger pharma. Comparable in targeting specialty/rare disease products across Europe.
• Consilient Health: UK- and Ireland-focused specialty pharma that in-licenses and markets mature specialty brands from larger manufacturers. Comparable mid-sized independent European specialty pharma model.
• Tillotts Pharma: Swiss specialty pharma specializing in gastroenterology and licensing acquired brands across Europe. Comparable in specialty-drug focus, EU country-by-country distribution, and acquisition-led portfolio building.
• Orphan Europe (Recordati Rare Diseases): French-headquartered rare disease specialty pharma (part of Recordati). Comparable in French specialty pharma operations, focus on essential mature drugs, and European commercial reach.

Broad incumbents

• CSL Vifor: Swiss specialty pharma (now under CSL) focused on iron deficiency, nephrology, and rare diseases. Comparable in European specialty focus and acquisition of late-stage deprioritized pharma assets, though larger and broader.
• Kyowa Kirin International: European specialty pharma arm of Japan-based Kyowa Kirin, marketing specialty therapeutics across multiple therapy areas in EU markets. Comparable in specialty pharma distribution and regulatory navigation across European countries.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HAC Pharma